Company Filing History:
5 out of 3,540 
1 out of 937 
1 out of 975 
Years Active: 2008-2014
Title: Louis M Staudt: Innovator in Lymphoma Research
Introduction
Louis M Staudt is a prominent inventor based in Silver Spring, MD (US), known for his significant contributions to the field of lymphoma research. He holds a total of five patents that focus on innovative methods for diagnosing and predicting survival in lymphoproliferative disorders. His work has had a profound impact on the understanding and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Latest Patents
Staudt's latest patents include groundbreaking discoveries such as the use of ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). His research revealed that high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL, providing methods for discriminating between clinical subgroups of patients. Additionally, he developed methods for identifying, diagnosing, and predicting survival in lymphomas based on gene expression data. This includes the invention of the Lymph Dx microarray, which allows for the analysis of gene expression patterns in lymphoma samples, aiding in accurate diagnosis and survival prediction.
Career Highlights
Throughout his career, Louis M Staudt has worked with esteemed organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and the University of Nebraska. His research has been pivotal in advancing the understanding of lymphoproliferative disorders and improving patient outcomes.
Collaborations
Staudt has collaborated with notable colleagues in the field, including Wyndham H Wilson and Andreas Rosenwald. These partnerships have further enhanced the impact of his research and innovations.
Conclusion
Louis M Staudt's contributions to lymphoma research through his patents and collaborations have significantly advanced the field. His innovative approaches continue to influence the diagnosis and treatment of lymphoproliferative disorders, ultimately benefiting patients worldwide.